Filing Flows › Delcath Systems (DCTH) › Q3 2026 › vs Q2 2026
Delcath Systems (DCTH) Q3 2026 vs Q2 2026 (quarter over quarter)
Delcath Systems's revenue rose $6.0M (+20%) from $29.1M in Q2 2026 to $35.1M in Q3 2026. The biggest changes: HEPZATO KIT +$5.5M (+20%); CHEMOSAT +$454K (+23%). Gross margin 88.8% against 89.8% (-0.9 pts).
Delcath Systems, Q3 2026: revenue $35.1M (+71% year over year), operating margin 20.3%, net earnings $7.0M, operating cash flow $8.2M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Gross margin | 88.8% | 89.8% | -0.9 pts |
| Operating margin | 20.3% | 8.2% | +12.1 pts |
| Net margin | 19.8% | 9.2% | +10.6 pts |
| Free cash flow margin | 19.7% | 17.9% | +1.8 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| HEPZATO KIT | $32.7M | $27.2M | $5.5M | +20% |
| CHEMOSAT | $2.4M | $2.0M | $454K | +23% |
| Revenue | $35.1M | $29.1M | $6.0M | +20% |
| Gross profit | $31.2M | $26.1M | $5.0M | +19% |
| Cost of revenue | $3.9M | $3.0M | $933K | +31% |
| Other income, net | $851K | $764K | $87K | +11% |
| Operating profit | $7.1M | $2.4M | $4.7M | +197% |
| Operating expenses | $24.1M | $23.8M | $315K | +1% |
| Pre-tax earnings | $8.0M | $3.2M | $4.8M | +152% |
| Research & development | $11.0M | $10.4M | $631K | +6% |
| SG&A | $13.1M | $13.4M | −$316K | -2% |
| Net earnings | $7.0M | $2.7M | $4.3M | +161% |
| Income tax | $1.0M | $491K | $524K | +107% |
| Depreciation | $200K | $100K | $100K | +100% |
| Share-based compensation | $4.2M | $5.1M | −$885K | -17% |
| Working capital & other | $3.2M | $2.2M | $1.0M | +48% |
| Operating cash flow | $8.2M | $5.7M | $2.5M | +43% |
| Free cash flow (OCF − capex) | $6.9M | $5.2M | $1.7M | +33% |
| Capital expenditures | $1.3M | $503K | $757K | +150% |
Questions
How much did Delcath Systems's revenue grow quarter over quarter in Q3 2026?
Delcath Systems's revenue rose $6.0M (+20%) from $29.1M in Q2 2026 to $35.1M in Q3 2026.
What drove Delcath Systems's revenue change in Q3 2026?
HEPZATO KIT +$5.5M (+20%); CHEMOSAT +$454K (+23%).